Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Lantern Pharma (NASDAQ:LTRN) will be featured on The RedChip Money Report on Bloomberg TV on April 16 at 7 p.m. ET. This program, which reaches approximately 73 million U.S. households, focuses on small-cap investing and includes interviews with company executives and Wall Street analysts. Lantern Pharma utilizes its RADR® AI platform for oncology drug discovery, with a pipeline of four drug candidates and an ADC program targeting eight tumor types, including two in phase 2 trials.
- Featured on The RedChip Money Report, enhancing visibility.
- Potential to showcase the company's innovative RADR® AI platform.
- Pipeline includes four drug candidates with promising phase 2 programs.
- None.
ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, will appear on The RedChip Money Report® on Bloomberg TV, April 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.
RedChip Companies Inc. produces the RedChip Money Report®. The show delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
To view the interview segment, please visit:
https://www.youtube.com/watch?v=YWY-qqsS-M0
About RedChip Companies, Inc.
RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. Founded in 1992, and headquartered in Orlando, Florida, RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.
Contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
LTRN@redchip.com
SOURCE: RedChip Companies Inc.
View source version on accesswire.com:
https://www.accesswire.com/697527/Lantern-Pharma-Interview-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR
FAQ
When will Lantern Pharma appear on The RedChip Money Report?
What is Lantern Pharma's focus in drug development?
How many drug candidates is Lantern Pharma developing?
What does the RADR® platform do for Lantern Pharma?
Where can I watch the interview segment with Lantern Pharma?
